RareCan
3 known investors
Find your way into RareCan
509 people in our graph share verified history with the RareCan team — schools, employers, funds. One of them is your warm intro.
Dominic Jacquessonunlockedknows Piers Kotting · together at University of Oxford (overlapped)
×4knows the team · via University of Oxford
knows the team · via Imperial College London
×2knows the team · via NHS England
×3knows the team · via UCL
knows the team · via Sevenoaks School
RareCan provides cancer treatment and clinical trial access tailored to individual patients, with a focus on improving outcomes for people diagnosed with rare cancers.
Founders & leadership
PK
Piers KottinginChief Executive OfficerPiers Kotting held clinical and managerial roles in NHS acute and mental health services before spending 15 years in research and development with the National Institute for Health and Care Research; he has founded multiple health tech companies and holds an MBA. As CEO of RareCan, he leads a platform connecting cancer patients with clinical trial and treatment opportunities tailored to rare cancer diagnoses.
SA
Simon AlloccainChief Financial OfficerHe brings corporate and investment banking experience, expertise in risk and governance, and background in business leadership and financial restructuring across multiple organizations.
Investors · 3
Also in the syndicate · 1
Women Angels of the North Syndicate
Funding
SEC filings, press & company announcements- Undisclosed amountseed funding roundJun 2022
Women Angels of the North Syndicate
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does RareCan do?
- RareCan provides cancer treatment and clinical trial access tailored to individual patients, with a focus on improving outcomes for people diagnosed with rare cancers.
- Who are RareCan's investors?
- RareCan's investors include Anglia Capital Group, Cambridge Angels group.